Emerging as a noteworthy breakthrough in the struggle against obesity, the drug is capturing considerable attention . It combines the action of two known GLP-1 receptor agonists, semaglutide , plus an unique glucose-dependent hormonal component. Early study data have demonstrated impressive fat decrease in patients with excessive weight, perhaps pr